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DISCHARGE AGAINST MEDICAL ADVICE (DAMA): THE CASE OF
PAYER STATUS
Mendonca CM, Banahan BF
University of Mississippi School of Pharmacy, University, MS, USA
OBJECTIVES: To examine the relationship between payer status and potential
confounders on DAMA using the National Hospital Discharge Survey. METHODS:
Retrospective analysis of a random, nationally representative sample of inpatient 
discharges in the US from 2004 to 2006. Patients represent discharges from short-
stay non-institutional hospitals in the US. Newborns and patients with an undeﬁ ned
payer status were excluded. Only patients with a routine or DAMA discharge status 
were included. A logistic regression analysis was performed modeling DAMA versus 
routine discharge as the outcome variable, with payer status as the primary predictor, 
and confounder variables, including gender, race, marital status, hospital type, 
geographic region, admission type and source, and drug abuse/addiction. Logistic
regression analysis was also performed after removing drug/alcohol abuse/addiction 
patients. RESULTS: From 2004 to 2006 DAMA accounted for 1.23% (n  946,232)
of all hospital discharges when drug and alcohol abuse/addiction patients are included
and 0.76% (n  510,556) when excluded. Controlling for the confounder variables, 
public (AOR  0.72, 95% CI  0.61–0.80) and privately (AOR  0.46, 95% CI 
0.40–0.52) insured patients are signiﬁ cantly less likely to DAMA than self-pay
patients. Consistent with the literature, males, African-Americans, private hospitals, 
emergency admissions, and drug (AOR  4.57, 95% CI  4.22–4.96) and alcohol
(AOR  5.00, 95% CI  4.46–5.61) abuse/addiction are signiﬁ cant risk factors for 
DAMA. Many of these relationships become stronger when substance abuse cases are
excluded. CONCLUSIONS: Considerable evidence exists that initiatives may be 
needed to better manage self-pay patients and ensure they do not DAMA. Further 
research should be done with longitudinal data to examine the relationship between
DAMA and health outcomes. Prior research indicates that DAMA predictors may also
be responsible for non-compliance of prescribed drug therapy, especially following
discharge. Therefore the potential for early pharmacist involvement has also been
identiﬁ ed.
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PHARMACIST OPINION AND PERCEIVED CONFIDENCE IN
KNOWLEDGE REGARDING THE IMPACT OF MEDICARE PART D
PRESCRIPTION DRUG BENEFIT PROGRAM ON PATIENT CARE
Goyal R, Makhija D, Sansgiry SS
University of Houston, Houston, TX, USA
OBJECTIVES: To determine pharmacist opinion regarding the impact of Medicare 
Part D prescription drug beneﬁ t program (MPD) on patient care and evaluate their
perceived conﬁ dence in knowledge regarding MPD. Further, the study assessed phar-
macists and practice site characteristics with their opinion and conﬁ dence. METHODS:
A prospective cross sectional survey (September 2006 to January 2007) was conducted 
using a convenient sample of 450 community pharmacists located in Houston. A scale
of 0 (low) to 100 (high) was used to measure perceived conﬁ dence consisting of 3 
items. The instrument included 11 items on a 5 point Likert scale from strongly 
disagree (1) to strongly agree (5) to measure pharmacists opinion on MPD namely,
patient satisfaction, quality of care, reimbursement gap, prescription coverage, dual
eligibility and plan selection. Descriptive statistics and comparative analyses were
performed with the coded data using SAS 9.1. RESULTS: The response rate was
52% (n  232). Mean (oSD) age of respondents was (36.7 o 7.6) years, with 50.9%
male, 56% staff pharmacist, 94% practicing in chain pharmacy, and 61.6% practicing
for less than 10 years. Overall, pharmacists were conﬁ dent (78 o 16.0) in their knowl-
edge about MPD. Pharmacist’s opinion in general was slightly positive (3.5 o 0.5) 
regarding the inﬂ uence of MPD on patient care. Signiﬁ cant differences (p  0.05) were 
observed by gender (male 82 vs. female75.4) and degree earned (BS 74 vs. PharmD
82.5) with respect to their conﬁ dence regarding MPD, respectively. Practice settings 
and pharmacist current positions did not seem to inﬂ uence their conﬁ dence regarding
MPD. Pharmacists perceived conﬁ dence was signiﬁ cantly correlated (p  0.05, r 
0.414) with their opinion regarding patient care domains of MPD. CONCLUSIONS:
Pharmacist’s characteristics play a role in their perceived conﬁ dence regarding 
their knowledge about MPD. Opinions regarding pharmacists on MPD aspects 
that would affect patient care were consistent across pharmacist characteristics and 
practice setting.
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ASSESSING THE EFFECT OF COST-SHARING ON EMERGENCY
DEPARTMENT USE BY ECONOMICALLY DISADVANTAGED PERSONS
Strassels SA1, Rascati KL2, Wilson JP2
1University of Texas at Austin College of Pharmacy, Austin, TX, USA, 2University of Texas at
Austin, Austin, TX, USA
OBJECTIVES: Emergency departments (ED) are designed to provide unexpected
care for seriously ill and injured persons, but people may seek care in EDs for other
reasons as well. In 2005, for example, 13.9% of ED visits in the United States were
considered non-urgent. Non-emergency use of the ED contributes to increased health
care costs and may indicate that access to health care is limited. The purpose of this
project was to describe and elicit determinants of ED use in a sample of economically
disadvantaged persons METHODS: We searched the published, English-language 
biomedical literature for articles on costs, cost-sharing, and ED use, for all years 
included in Medline, 1950 to the present. RESULTS: In 2005, of 115.3 million ED 
visits, 13.9% were considered non-urgent (requiring attention within 2–24 hours). In 
an analysis of data from 2000–2001, Hunt et al found that frequent (4/year) ED use
was positively associated with poor physical and mental health. Hsu et al reported 
that ED copays in insured persons from $1 to $100 were associated with lower ED
use, but not with poor outcomes. Wharam et al found that, from 2001–2005, higher-
deductible insurance was associated with decreased ED visits among persons with 
employer-based health insurance, but not with a decrease in the odds for a ﬁ rst ED
visit. CONCLUSIONS: Programs to decrease ED use, such as cost-sharing, have been
evaluated, but studies to evaluate these types of policies have typically focused on 
insured individuals. As a result, there is an important gap in understanding the epide-
miology and economics of ED use among low-income, uninsured, and underinsured
persons.
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HOW DO MANAGED PHYSICIAN PANELS COMPARE AGAINST
NON-PANEL PHYSICIANS FOR THE PURPOSE OF RESEARCH?
Narayanan S
TNS Healthcare, New York, NY, USA
OBJECTIVES: Clinical investigator databases, prescriber-list and ad-hoc sources
often constitute the physician pool for epidemiological and outcomes-research initia-
tives. Use of “managed physician panels” for such research purpose is not yet common. 
This study aims to compare demographics, prescribing patterns and attitudes/
opinions between physicians in ‘managed panels’ and free-bound non-panel sample in 
the U.S. METHODS: TNS manages J-Street Panel, a managed panel of over 25,000 
physicians in the U.S across 35 specialties. A small proportion of these physicians, 
especially allergists/pulmonologists, were recruited online, and another cohort from 
free-bound (non-panel) sample was recruited via telephone for a research initiative. 
Practice characteristics, treatment dynamics and attitudes/opinions were measured 
in both cohorts using a standardized 30-minute-survey; the results were analyzed 
to assess any statistical difference between the panelists and non-panelists across 
the measured domains. RESULTS: Survey results from allergists/pulmonologists 
(83-panelists & 68-non-panelists) speciﬁ cally in the COPD/Asthma categories were
assessed. There were no statistically signiﬁ cant differences observed between the
cohorts in practice characteristics: percent of time spent in clinical practice, number
of COPD and/or Asthma patients seen in a typical month, percent of COPD patients 
with no asthma, and percent of asthma patients with no COPD, with years of 
clinical-practice alone differing between cohorts (panelists-14 yrs/non-panelists-
17 yrs); no differences observed in treatment choices (including, percent of patients
prescribed a maintenance medication for their asthma and/or COPD) and treatment 
practices (9-item-domain), with the same prescribing levels holding true across all 
medications and dosage strengths. CONCLUSIONS: This is one of the ﬁ rst studies to 
quantitatively compare managed panel of physicians to their non-panel counterparts 
in the U.S and the results showed no statistical differences between the cohorts in the 
measured domains. Managed panels are viable options for scientiﬁ c research studies, 
as they provide robust, cost-effective, quick sample of physicians, with relatively high
response rate.
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PATIENT PRIVACY AND DATA CONFIDENTIALITY AND THE USE OF 
SECONDARY DATA
Dean BB1, Aguilar D1, Whyte J2, Nordyke R2
1Cerner LifeSciences, Beverly Hills, CA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA
OBJECTIVES: No well-deﬁ ned standards, including provisions in HIPAA, currently 
provide clear guidance for merging, linking, and analyzing secondary health data 
that were originally collected for patient care, such as electronic medical record 
(EMR) data. A literature review explored factors that may affect potential risks
of secondary data research from the perspective of patient privacy and data
con ﬁ dentiality. METHODS: The PubMed database and internet sites of CDC, DHHS,
and patient advocacy groups were searched to identify publications from January 1, 
1998 to March 7, 2008 involving patient privacy and secondary use of data. Search
terms included (but were not limited to): conﬁ dentiality, privacy, consent, ethics, 
secondary data, secondary analysis, patient data, de-identiﬁ ed, and identiﬁ able. 
RESULTS: A total of 33 documents were identiﬁ ed. Several discussion topics that
address patient privacy within the context of secondary data research were identiﬁ ed 
in the literature. These issues were assessed and grouped into four domains: 1) con-
cerns about inadequacy of patient consent [76% of articles] (eg, no patient consent is
needed or that consent obtained for general research purposes may not be adequate
for speciﬁ c research hypotheses); 2) concerns about identiﬁ ability of the data and 
the degree to which the data can be de-identiﬁ ed [88%]; 3) concerns about data 
access, including monitoring, controlling, and regulation of data access [85%]; and
(4) concerns about the investigators’ objectives for analyzing and using the data [52%] 
(eg, epidemiology and surveillance studies caused less concern than did market
research). CONCLUSIONS: We identiﬁ ed four recurrent themes in the evidence: 
they touched upon patient consent, identiﬁ ability of data, data access, and research 
objectives. Dialogue about these issues between investigators, research oversight 
administrators and patient advocates may help clarify standards to ensure that second-
ary data research is broadly acceptable from a patient privacy and data conﬁ dentiality 
perspective.
